Erin E. Longbrake

TL;DR: The controversies in the field are evaluated and the remaining scientific challenges that are associated with enhancing immune function in the CNS to treat neurological diseases are discussed.

TL;DR: It is found that SCI elicits below-level allodynia of similar magnitude to at-level pain caused by a peripheral nerve injury, and the presence of robust microglial activation in L5 cord predicted allodyia in 86% of rats, suggesting that remote microglia activation is pivotal in the development and maintenance of below- level allodynian after SCI.

TL;DR: Blockade of CX3CR1 signaling represents a selective anti-inflammatory therapy that is able to promote neuroprotection, in part by reducing inflammatory signaling in microglia and MDMs and recruitment of a novel monocyte subset.

TL;DR: Misdiagnosis of MS leads to unnecessary and potentially harmful risks to patients and leading factors contributing to misdiagnosis were consideration of symptoms atypical for demyelinating disease, lack of corroborative objective evidence of a CNS lesion as satisfying criteria for MS attacks, and overreliance on MRI abnormalities in patients with nonspecific neurologic symptoms.

TL;DR: Whether lymphopenic or not, DMF-treated patients had a lower proportion of circulating central and effector memory T cells and concomitant expansion of naïve T cells compared to the controls, regardless of the absolute lymphocyte count.